Inion Oyj - Company Announcement

Inion granted annual reporting exemptions from the Finnish Financial Supervisory Authority

Inion Oy
(“Inion or the “Company”)

Inion granted annual reporting exemptions from the Finnish Financial
Supervisory Authority 

Tampere, Finland and Guildford, UK. 2 March 2009, Inion (LSE: IIN.L), a company
focused on the development and commercialisation of novel biodegradable medical
implants, announces that it has been granted exemption from certain of its
financial reporting obligations by the Finnish Financial Supervisory Authority
(FIN-FSA). The exemption applies only until the end of April 2009 and allows
Inion to report its annual accounts and annual report more in accordance with
reporting rules for companies listed on the Main Market of the London Stock
Exchange. In particular, the exemption provides that: 

•	the public announcement of the annual accounts relating to 2008 shall take
place within four months after the end of the financial period, rather than
within three months (Inion's financial year end is 31 December), 

•	the annual accounts and the annual report shall be published one week before
the AGM at the latest, and the AGM shall be held within six months after the
end of the financial period, 

•	the FIN-FSA also grants an exemption from the obligation to publish an annual
compendium of releases for 2008. 

The FIN-FSA is not able to grant exemption from the obligation to finalise the
accounts within four months from the end of the financial period (as provided
in the Act on Book-keeping) and from the obligation to hold the AGM to approve
the accounts within six months from the end of the financial period (as
provided in the UK Companies Act). 

- Ends -

For further information, please contact:

Inion Oy 
Chris Lee, Chief Executive Officer
Julien Cotta, Chief Financial Officer
Tel: +44 (0)1483 685390

Citigate Dewe Rogerson
Mark Swallow / David Dible / Helena Galilee	
Tel: +44 (0)207 638 9571


About Inion (www.inion.com)
Inion Oy is a medical devices company focused on the development and successful
commercialisation of innovative and unique biodegradable and bioactive surgical
implants in selected high value orthopaedic market segments. 

Inion's core expertise and technology lies in the design and manufacture of
innovative biodegradable plates, screws, pins and membranes, which are used to
enhance the healing of bone or soft tissue injuries to the skeleton, such as
those caused by trauma or by reconstructive surgery. Inion implants are made
from its proprietary Inion Optima™ family of biomaterials, with properties
tailored for specific surgical applications, in terms of strength, flexibility
and rate of degradation 
 
Inion is also focused on developing proprietary new bioactive and biodegradable
biomaterials that promote bone healing and accelerate patient rehabilitation. 

Inion was incorporated in early 2000 and listed on the Official List of the UK
Listing Authority in December 2004 (ticker: IIN). The Company has offices in
the UK and USA, and its head office, R&D and production facilities are in
Tampere, Finland. 

This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as
the words "targets", "believes", "estimates", "expects", "aims", "intends",
"will", "can", "may", "anticipates", "would", "should", "could" or similar
expressions or the negative thereof. Such forward-looking statements involve
known and unknown risks, uncertainties and other important factors beyond the
Group's control that could cause the actual results, performance or
achievements of the Group to be materially different from future results,
performance or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous assumptions
regarding the Group's present and future business strategies and the
environment in which the Group will operate in the future. Among the important
factors that could cause the Group's actual results, performance or
achievements to differ materially from those in forward-looking statements
include those relating to Inion's funding requirements, regulatory approvals,
reliance on third parties, intellectual property, key personnel and other
factors. These forward-looking statements speak only as at the date of this
announcement. The Group expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking statements
contained in this announcement to reflect any change in the Group's
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based. As a result of these
factors, prospective investors are cautioned not to rely on any forward-looking
statement.